Premium
Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double‐blind, placebo‐controlled trial
Author(s) -
Anzić S.A.,
Turkalj M.,
Župan A.,
Labor M.,
Plavec D.,
Baudoin T.
Publication year - 2018
Publication title -
clinical otolaryngology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.914
H-Index - 68
eISSN - 1749-4486
pISSN - 1749-4478
DOI - 10.1111/coa.13005
Subject(s) - medicine , omeprazole , placebo , laryngopharyngeal reflux , proton pump inhibitor , gastroenterology , reflux , randomized controlled trial , disease , pathology , alternative medicine
Objectives Gastroesophageal reflux recommended treatment (dose and duration) with proton‐pump inhibitor (PPI) compared to placebo significantly reduces the signs and symptoms of laryngopharyngeal reflux (LPR) and comorbid chronic rhinosinusitis (CRS). Design Double‐blind randomised placebo‐controlled trial. Setting Eight weeks of treatment with omeprazole 20 mg once daily (OD). Participants Sixty patients (28 women, aged 19‐87 years) with diagnosed LPR and comorbid CRS. Main outcome measures Significant reduction in signs and symptoms (reflux symptom index (RSI) score as subjective, and reflux finding score (RFS) as objective measure) of LPR after 8 weeks of treatment with omeprazole 20 mg OD when compared to placebo. Secondary objectives were significant reduction in signs and symptoms of comorbid CRS after 8 weeks of treatment with omeprazole 20 mg OD when compared to placebo and the association of the severity of signs and symptoms of LPR with the ones of CRS. Results RSI and RFS decreased significantly more in the active treatment group after 8 weeks compared to placebo ( P < .001 for both). CRS and endoscopy scoring decreased both significantly more in the active group after 8 weeks compared to placebo ( P < .001 for both). CRS scoring significantly correlated with RSI ( R = 0.312, P = .015) but not with RFS ( R = 0.199, P = .127). Conclusions The results of our trial suggest that omeprazole 20 mg OD for 8 weeks was effective in reducing signs and symptoms of both LPR and CRS, although in most patients still present at the end of the trial.